FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We es...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Azuma, Koichi, Kawahara, Akihiko, Sonoda, Kahori, Nakashima, Kazutaka, Tashiro, Kousuke, Watari, Kosuke, Izumi, Hiroto, Kage, Masayoshi, Kuwano, Michihiko, Ono, Mayumi, Hoshino, Tomoaki
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171601/
https://ncbi.nlm.nih.gov/pubmed/25115383
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky